Pharvaris N.V. (PHVS): who owns it and who trades it
As of Nov 16, 2026, PHVS insiders reported 65 open-market sales worth $32.5M and no purchases in the last 12 months, with 0% of the sale value made under pre-set 10b5-1 plans. The largest seller was Johannes Gerardus Christiaan Petrus Schikan (Director), with $9.7M. 5 of the 50 famous funds we follow held it at their last quarter end.
Latest filing Nov 16, 2026. From Form 4, 13F and Schedule 13D/G filings.
At a glance
Who is buying and selling Pharvaris
From the latest filingsOverall: about as much buying as selling. Insiders mostly sold. Funds and famous investors mostly bought.
Each group counts equally in the meter, by the number of buyers and sellers, not dollars. Insider sales under pre-set 10b5-1 plans are left out of it. From SEC, House and Senate filings; not advice.
Who owns PHVS
125 funds and institutions reported PHVS shares worth $2.3B at the end of Q2 2026. Some shares are counted by more than one filer, or lent out and counted twice, so the total can pass 100%. The largest holder is FMR LLC (Fidelity) with 10.1%.
Funds and institutions (13F) about 100%Everyone else 0%
10 largest owners, by share of the company
Top 20 owners
| Owner | Shares | % of company | Value | Change since Q1 2026 |
|---|---|---|---|---|
| FMR LLC (Fidelity) | 6.57M | 10.07% | $227M | +4% |
| General Atlantic, L.P. | 6.55M | 10.05% | $227M | -18% |
| Foresite Capital Management IV, LLC | 4.78M | 7.33% | $165M | No change |
| VenBio Partners LLC | 4.64M | 7.12% | $161M | +0% |
| Viking Global Investors LP | 3.65M | 5.60% | $126M | No change |
| EQT Fund Management S.a r.l. | 3.42M | 5.25% | $118M | No change |
| Deerfield Management Company, L.P. | 3.38M | 5.18% | $117M | +8% |
| Bain Capital Life Sciences Investors, LLC | 2.68M | 4.10% | $92.5M | No change |
| Wellington Management Group LLP | 2.39M | 3.67% | $82.7M | +13% |
| Polar Capital Holdings Plc | 2.33M | 3.57% | $80.4M | +198% |
| Point72 Asset Management, L.P. | 1.64M | 2.52% | $56.8M | +63% |
| Commodore Capital LP | 1.43M | 2.19% | $49.3M | -26% |
| Novo Holdings A/s | 1.40M | 2.15% | $48.4M | -20% |
| Saturn V Capital Management LP | 1.31M | 2.02% | $45.4M | +9% |
| TCG Crossover Management, LLC | 1.01M | 1.55% | $34.9M | – |
| Sofinnova Investments, Inc. | 881,299 | 1.35% | $30.5M | +8% |
| California State Teachers Retirement System | 799,490 | 1.23% | $23.1M | +3210% |
| 5AM Venture Management, LLC | 797,600 | 1.22% | $27.6M | No change |
| Seven Fleet Capital Management LP | 774,501 | 1.19% | $26.8M | +348% |
| BlackRock, Inc. | 771,454 | 1.18% | $26.7M | +2% |
From the SEC 13F data sets: every fund manager with over $100M must report its US stock holdings every 3 months, up to 45 days after the quarter ends. Owners are shown as they file, so one group (for example Vanguard) can appear under several names. Individuals, most insiders and smaller funds do not file 13F reports.
Insider trades
In the last 12 months, PHVS insiders reported $0 of open-market purchases and $32.5M of sales. 0% of the sale value was under a 10b5-1 plan, a schedule set up in advance.
Purchases and sales by month
Latest trades
| Date | Insider | Role | Type | Shares | Price | Value | Filing |
|---|---|---|---|---|---|---|---|
| Sep 23, 2026 | Viviane Monges | Director | Sale | 11,969 | $33.05 | $396K | Form 4 |
| Sep 22, 2026 | Johannes Gerardus Christiaan Petrus Schikan | Director | Sale | 800 | $36.19 | $29K | Form 4 |
| Sep 21, 2026 | David W. Nassif | CFO | Sale | 6,000 | $36.47 | $219K | Form 4 |
| Sep 17, 2026 | Peng Lu | President | Sale | 100,000 | $35.00 | $3.5M | Form 4 |
| Sep 17, 2026 | Johannes Gerardus Christiaan Petrus Schikan | Director | Sale | 200,000 | $35.00 | $7M | Form 4 |
| Sep 17, 2026 | Elisabeth Bjork | Director | Sale | 52,500 | $37.89 | $2M | Form 4 |
| Sep 17, 2026 | Robert Glassman | Director | Sale | 14,493 | $38.56 | $559K | Form 4 |
| Sep 17, 2026 | Anne Lesage | Chief Early Development | Sale | 20,000 | $38.27 | $765K | Form 4 |
| Sep 15, 2026 | Stefan Andreas Abele | Chief Technical Ops Offi | Sale | 1,400 | $39.24 | $54.9K | Form 4 |
| Sep 15, 2026 | Stefan Andreas Abele | Chief Technical Ops Offi | Sale | 45,000 | $38.14 | $1.7M | Form 4 |
| Sep 15, 2026 | Robert Glassman | Director | Sale | 8,667 | $38.27 | $332K | Form 4 |
| Sep 15, 2026 | Wim Souverijns | Chief Commercial Officer | Sale | 6,090 | $38.99 | $237K | Form 4 |
| Sep 14, 2026 | Wim Souverijns | Chief Commercial Officer | Sale | 20,000 | $39.31 | $786K | Form 4 |
| Sep 14, 2026 | Berndt Modig | CEO | Sale | 2,291 | $39.40 | $90.3K | Form 4 |
| Sep 11, 2026 | Peng Lu | President | Sale | 15,000 | $40.13 | $602K | Form 4 |
| Sep 10, 2026 | Anne Lesage | Chief Early Development | Sale | 30,000 | $38.30 | $1.1M | Form 4 |
| Sep 9, 2026 | Robert Glassman | Director | Sale | 8,000 | $37.55 | $300K | Form 4 |
| Sep 8, 2026 | Peng Lu | President | Sale | 15,000 | $40.68 | $610K | Form 4 |
| Aug 14, 2026 | Berndt Modig | CEO | Sale | 2,292 | $34.77 | $79.7K | Form 4 |
| Jul 13, 2026 | Berndt Modig | CEO | Sale | 2,292 | $34.97 | $80.2K | Form 4 |
| Jun 30, 2026 | Johannes Gerardus Christiaan Petrus Schikan | Director | Sale | 30,712 | $35.49 | $1.1M | Form 4 |
| Jun 30, 2026 | Anne Lesage | Chief Early Development | Sale | 27,872 | $35.48 | $989K | Form 4 |
| Jun 30, 2026 | Anne Lesage | Chief Early Development | Sale | 30,703 | $35.49 | $1.1M | Form 4 |
| Jun 29, 2026 | Johannes Gerardus Christiaan Petrus Schikan | Director | Sale | 6,888 | $35.05 | $241K | Form 4 |
| Jun 29, 2026 | Anne Lesage | Chief Early Development | Sale | 2,300 | $35.12 | $80.8K | Form 4 |
| Jun 29, 2026 | Anne Lesage | Chief Early Development | Sale | 8,300 | $35.05 | $291K | Form 4 |
| Jun 29, 2026 | Anne Lesage | Chief Early Development | Sale | 6,997 | $35.05 | $245K | Form 4 |
| Jun 29, 2026 | Johannes Gerardus Christiaan Petrus Schikan | Director | Sale | 2,400 | $35.10 | $84.2K | Form 4 |
| Jun 26, 2026 | Peng Lu | Chief Medical Officer | Sale | 14,700 | $34.00 | $500K | Form 4 |
| Jun 25, 2026 | Anne Lesage | Chief Early Development | Sale | 2,300 | $35.12 | $80.8K | Form 4 |
| Jun 25, 2026 | Peng Lu | Chief Medical Officer | Sale | 3,400 | $35.09 | $119K | Form 4 |
| Jun 25, 2026 | Peng Lu | Chief Medical Officer | Sale | 11,600 | $34.45 | $400K | Form 4 |
| Jun 18, 2026 | Peng Lu | Chief Medical Officer | Sale | 300 | $34.00 | $10.2K | Form 4 |
| Jun 15, 2026 | Berndt Modig | CEO | Sale | 100 | $31.46 | $3.1K | Form 4 |
| Jun 15, 2026 | Berndt Modig | CEO | Sale | 2,191 | $31.05 | $68K | Form 4 |
| Jun 4, 2026 | Anna Nijdam | Principal Accounting Off | Sale | 2,670 | $30.87 | $82.4K | Form 4 |
| May 22, 2026 | Anna Nijdam | Principal Accounting Off | Sale | 5,501 | $30.74 | $169K | Form 4 |
| May 21, 2026 | Viviane Monges | Director | Sale | 9,667 | $30.29 | $293K | Form 4 |
| May 21, 2026 | Anna Nijdam | Principal Accounting Off | Sale | 1,829 | $30.60 | $56K | Form 4 |
| May 21, 2026 | David W. Nassif | CFO | Sale | 10,000 | $30.31 | $303K | Form 4 |
| May 20, 2026 | Elisabeth Bjork | Director | Sale | 10,000 | $29.32 | $293K | Form 4 |
| May 18, 2026 | Berndt Modig | CEO | Sale | 2,292 | $29.22 | $67K | Form 4 |
| May 15, 2026 | Robert Glassman | Director | Sale | 5,333 | $29.83 | $159K | Form 4 |
| May 15, 2026 | Robert Glassman | Director | Sale | 4,667 | $29.82 | $139K | Form 4 |
| May 15, 2026 | Stefan Andreas Abele | Chief Technical Ops Offi | Sale | 8,748 | $29.82 | $261K | Form 4 |
| May 15, 2026 | Wim Souverijns | Chief Commercial Officer | Sale | 10,000 | $29.92 | $299K | Form 4 |
| May 1, 2026 | Peng Lu | Chief Medical Officer | Sale | 14,023 | $30.16 | $423K | Form 4 |
| May 1, 2026 | Peng Lu | Chief Medical Officer | Sale | 143 | $31.00 | $4.4K | Form 4 |
| Apr 30, 2026 | Johannes Gerardus Christiaan Petrus Schikan | Director | Sale | 670 | $31.03 | $20.8K | Form 4 |
| Apr 30, 2026 | Johannes Gerardus Christiaan Petrus Schikan | Director | Sale | 28,400 | $30.30 | $861K | Form 4 |
| Apr 30, 2026 | Anne Lesage | Chief Early Development | Sale | 19,200 | $30.26 | $581K | Form 4 |
| Apr 30, 2026 | Anne Lesage | Chief Early Development | Sale | 18,000 | $30.26 | $545K | Form 4 |
| Apr 30, 2026 | Anne Lesage | Chief Early Development | Sale | 3,700 | $30.26 | $112K | Form 4 |
| Apr 30, 2026 | Peng Lu | Chief Medical Officer | Sale | 15,000 | $30.24 | $454K | Form 4 |
| Apr 29, 2026 | Johannes Gerardus Christiaan Petrus Schikan | Director | Sale | 3,830 | $30.07 | $115K | Form 4 |
| Apr 29, 2026 | Anne Lesage | Chief Early Development | Sale | 3,700 | $30.08 | $111K | Form 4 |
| Apr 29, 2026 | Anne Lesage | Chief Early Development | Sale | 3,700 | $30.06 | $111K | Form 4 |
| Apr 29, 2026 | Peng Lu | Chief Medical Officer | Sale | 3,733 | $30.06 | $112K | Form 4 |
| Apr 23, 2026 | Johannes Gerardus Christiaan Petrus Schikan | Director | Sale | 100 | $30.03 | $3K | Form 4 |
| Apr 22, 2026 | Johannes Gerardus Christiaan Petrus Schikan | Director | Sale | 7,000 | $30.05 | $210K | Form 4 |
| Apr 22, 2026 | Anne Lesage | Chief Early Development | Sale | 500 | $30.00 | $15K | Form 4 |
| Apr 22, 2026 | Peng Lu | Chief Medical Officer | Sale | 7,001 | $30.05 | $210K | Form 4 |
| Apr 16, 2026 | Berndt Modig | CEO | Sale | 2,292 | $28.60 | $65.6K | Form 4 |
| Apr 9, 2026 | Berndt Modig | CEO | Sale | 23,133 | $27.74 | $642K | Form 4 |
| Apr 9, 2026 | Berndt Modig | CEO | Sale | 200 | $28.42 | $5.7K | Form 4 |
Insiders by value traded
| Insider | Role | Bought | Sold | Last trade |
|---|---|---|---|---|
| Johannes Gerardus Christiaan Petrus Schikan | Director | – | $9.7M | Sep 22, 2026 |
| Peng Lu | Chief Medical Officer | – | $6.9M | Sep 17, 2026 |
| Anne Lesage | Chief Early Development | – | $6.2M | Sep 17, 2026 |
| Elisabeth Bjork | Director | – | $2.3M | Sep 17, 2026 |
| Stefan Andreas Abele | Chief Technical Ops Officer | – | $2M | Sep 15, 2026 |
| Robert Glassman | Director | – | $1.5M | Sep 17, 2026 |
| Wim Souverijns | Chief Commercial Officer | – | $1.3M | Sep 15, 2026 |
| Berndt Modig | Chief Executive Officer, Director | – | $1.1M | Sep 14, 2026 |
| Viviane Monges | Director | – | $688K | Sep 23, 2026 |
| David W. Nassif | CFO / CLO | – | $522K | Sep 21, 2026 |
| Anna Nijdam | Principal Accounting Officer | – | $307K | Jun 4, 2026 |
What this data shows, and what it doesn't
- Shows: open-market purchases and sales by officers, directors and 10%+ owners, reported on Form 4 within two business days of the trade.
- Leaves out: stock awards, option exercises, shares withheld for tax and gifts. These are not trades at a market price chosen by the insider.
- "plan" marks a sale made under a Rule 10b5-1 plan, a schedule set up in advance.
- Fund holders come from 13F reports, a snapshot at quarter end filed up to 45 days later.
- Filings are self-reported and can be amended. Each trade links to its original filing. Methodology
PHVS short interest
2.54M PHVS shares are sold short. Over the last 12 reports the number of shares short went up 323%.
As of Oct 30, 2026, 2.54M PHVS shares were sold short, up 3.0% from the report before. At the average daily volume of 708,619 shares, buying them all back would take about 3.6 trading days (days to cover).
Shares short, % of all shares
Days to cover
Every report
| Settlement date | Shares short | % of shares | Change | Avg daily volume | Days to cover |
|---|---|---|---|---|---|
| Oct 30, 2026 | 2.54M | – | +3% | 708,619 | 3.6 |
| Oct 15, 2026 | 2.47M | – | +23% | 614,033 | 4.0 |
| Sep 30, 2026 | 2.01M | – | +13% | 707,991 | 2.8 |
| Sep 15, 2026 | 1.78M | – | -17% | 1.44M | 1.2 |
| Aug 31, 2026 | 2.16M | – | +22% | 638,810 | 3.4 |
| Aug 14, 2026 | 1.78M | – | +49% | 638,201 | 2.8 |
| Jul 31, 2026 | 1.19M | – | +5% | 313,550 | 3.8 |
| Jul 15, 2026 | 1.14M | 1.74% | +15% | 676,462 | 1.7 |
| Jun 30, 2026 | 985,973 | 1.51% | -12% | 434,694 | 2.3 |
| Jun 15, 2026 | 1.12M | 1.72% | +58% | 377,862 | 3.0 |
| May 29, 2026 | 708,630 | 1.09% | +18% | 270,617 | 2.6 |
| May 15, 2026 | 600,645 | 0.92% | -43% | 463,899 | 1.3 |
Short sellers borrow shares and sell them, hoping to buy them back for less. A high number means many such bets are open. It does not say where the price will go. Source: FINRA equity short interest, reported by brokers twice a month (positions on the 15th and the last business day) and published about 7 business days later. % of shares uses the share count on the company's latest SEC filing. What short interest means · Most shorted stocks
Famous investors that hold PHVS
5 of the 50 well-known investors we track reported holding PHVS in their latest 13F filing. The largest position is Andreas Halvorsen's, worth $93M.
Position size
All holders
| Fund | Quarter | Shares | Value | Of portfolio | Change |
|---|---|---|---|---|---|
| Andreas Halvorsen · Viking Global Investors | Q3 2026 | 2.93M | $93M | 0.3% | -20% |
| Steve Cohen · Point72 Asset Management | Q3 2026 | 2.90M | $92M | 0.2% | +77% |
| Ken Griffin · Citadel Advisors | Q3 2026 | 483,054 | $15.3M | 0.0% | +100% |
| Israel Englander · Millennium Management | Q3 2026 | 309,160 | $9.8M | 0.0% | -28% |
| Paul Tudor Jones · Tudor Investment Corp | Q3 2026 | 13,523 | $429K | 0.0% | +3% |
From 13F reports: a snapshot at quarter end, filed up to 45 days later. Change compares with the quarter before.
5%+ stakes filed in the last 120 days
Anyone who owns more than 5% of a company must report it on Schedule 13D or 13G. 6 filings named PHVS in the last 120 days.
| Filed | Holder | Form | Stake |
|---|---|---|---|
| Nov 16, 2026 | Wellington Management Group LLP | 13G | 9.5% |
| Nov 16, 2026 | Wellington Management Group LLP | 13G | 9.5% |
| Nov 16, 2026 | VIKING GLOBAL INVESTORS LP | 13G/A | 4.5% |
| Nov 16, 2026 | VIKING GLOBAL INVESTORS LP | 13G/A | 4.5% |
| Nov 13, 2026 | GENERAL ATLANTIC, L.P. | 13G/A | 0.6% |
| Nov 13, 2026 | GENERAL ATLANTIC, L.P. | 13G/A | 0.6% |
Questions about Pharvaris N.V. (PHVS) stock
Who owns the most PHVS stock?
The largest reported owner of Pharvaris N.V. (PHVS) is FMR LLC (Fidelity), with 10.1% of the company. In total, 125 funds and institutions reported holding PHVS at the end of Q2 2026, together about 100% of the shares. See the largest owners.
Are PHVS insiders buying or selling?
In the last 12 months, PHVS insiders reported no open-market purchases and 65 sales worth $32.5M. The latest trade was on Sep 23, 2026. See every trade.
What is the short interest in PHVS?
As of Oct 30, 2026, 2.54M PHVS shares were sold short, up 3.0% from the report before. At the average daily volume of 708,619 shares, buying them all back would take about 3.6 trading days (days to cover). See the history.
Which famous investors hold PHVS?
5 of the 50 well-known investors we track reported PHVS in their latest 13F filing, including Andreas Halvorsen, Steve Cohen, Ken Griffin. The largest position is worth $93M. See all holders.
Source: SEC Form 4 (insiders, filed within 2 business days), 13F (funds, up to 45 days after quarter end) and Schedule 13D/13G filings. Only open-market purchases (code P) and sales (code S) are shown. Data only, not investment advice. How we collect it.